Effectiveness of omalizumab in a patient with severe asthma and atopic dermatitis

Submitted: January 26, 2016
Accepted: January 26, 2016
Published: January 26, 2016
Abstract Views: 1226
PDF: 657
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


The anti-IgE antibody omalizumab is currently indicated in severe asthma not controlled by standard drug therapy. Recently, new indications for omalizumab were suggested, which include atopic dermatitis (AD), a skin disorder characterized by elevated levels of IgE. We report the case of a 39-year old woman with severe asthma and severe AD, both resistant to conventional drug treatment. The patient had a IgE level of 1304 kU/L, which exceeded the recommended maximum level for treating asthma with omalizumab (stated in 700 Ku/L) but was far lower than previously reported in cases of AD treated with anti-IgE. The treatment consisted of a dose of omalizumab 375 mg every two weeks, and induced a rapid improvement of asthma, with no need of other drugs after three months, along with a progressive decline of severity of AD, which after five months was completely cured. These findings suggest the usefulness of omalizumab in patients with concomitant severe asthma and AD, also considering the pharmaco-economic balance obtained by withdrawing the multiple drugs used to treat both diseases.



PlumX Metrics


Download data is not yet available.


How to Cite

Incorvaia, C., C. Pravettoni, M. Mauro, M.-R. Yacoub, F. Tarantini, and G.G. Riario-Sforza. 2016. “Effectiveness of Omalizumab in a Patient With Severe Asthma and Atopic Dermatitis”. Monaldi Archives for Chest Disease 69 (2). https://doi.org/10.4081/monaldi.2008.401.